Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
The DOI matches its Crossref record.
Abstract
Cushing's syndrome is a rare disease with significant morbidity and mortality. Surgical intervention represents the most effective treatment option in both adrenocorticotropin-dependent and -independent forms of hypercortisolism. It is not uncommon, however, that surgery fails to cure or control the disease. Pharmacotherapy with drugs inhibiting steroid biosynthesis can be effectively used in these cases in order to alleviate symptoms or even to induce chemical adrenalectomy. A few drugs inhibiting single or multiple steps in adrenal steroid biosynthesis can be used in clinical practice. Drugs predominantly inhibiting single enzymatic steps include the 11beta-hydroxylase inhibitor metyrapone and the 3beta-hydroxysteroid dehydrogenase inhibitor trilostane, whereas mitotane, aminoglutethimide, ketoconazole and etomidate block multiple enzymatic reactions. Etomidate is the only agent available for parenteral administration that renders it as a treatment of choice in critically ill patients requiring a rapid control of hypercortisolemia. Ketoconazole, metyrapone and aminoglutethimide can be used alone or in combination for the treatment of hypercortisolism caused by benign adrenocorticotropin- or cortisol-secreting tumors. The clinical utility of trilostane is variable. Besides blocking multiple steps in adrenal steroid biosynthesis, the DDT (insecticide) analogue mitotane also has adrenolytic properties by inducing mitochondrial degeneration that renders it superior to other drugs in the treatment of adrenocortical cancer. Severe side effects may develop during therapy with each aforementioned drug that include hepatic, endocrine and neurological toxicity. After summarizing the chemical and biological properties of steroid biosynthetic inhibitors, the authors describe their possible clinical applications and limitations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Clinical and Molecular Pharmacology of Etomidate
Forman, S. A., & Warner, D. S. (2011) · Anesthesiology · doi:10.1097/aln.0b013e3181ff72b5 · Cited by 361
Kroiss, M., Quinkler, M., Lutz, W. K., Allolio, B., & Fassnacht, M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04214.x · Cited by 148
Tanaka, T., Satoh, F., Ujihara, M., Midorikawa, S., Kaneko, T., Takeda, T., Suzuki, A., Sato, M., & Shimatsu, A. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0617 · Cited by 44
The gut microbiota affects corticosterone production in the murine small intestine
Ergang, P., Vagnerová, K., Hermanová, P., Vodička, M., Jágr, M., Šrůtková, D., Dvořáček, V., Hudcovic, T., & Pácha, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084229 · Cited by 37
“AMG blocks the first step of steroid biogenesis by inhibiting the cholesterol side-chain cleavage enzyme (CYP11a1), whereas metyrapone inhibits glucocorticoid synthesis by inhibiting 11β-hydroxylase (CYP11b1) [31] and regeneration of corticosterone from 11-dehydrocorticosteroen by inhibiting 11β-hydroxysteroid dehydro…”
BackgroundMethod
Metadata
- Authors
- Igaz, P., Tombol, Z., Szabo, P., Liko, I., & Racz, K.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-11-01
- Volume
- 15
- Issue
- 26
- Pages
- 2734-2747
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2101248051
- Cited by
- 55
- References
- 0
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice. https://app.cochat.ai/papers/10.2174/092986708786242921
- The paper
- Igaz, P., Tombol, Z., Szabo, P., Liko, I., & Racz, K. (2008). Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice. Current Medicinal Chemistry. https://doi.org/10.2174/092986708786242921
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.